Insider Transactions in Q1 2024 at Cyma Bay Therapeutics, Inc. (CBAY)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2024
|
Charles Mc Wherter President of R&D |
SELL
Sale (or disposition) back to the issuer
|
Direct |
46,938
-100.0%
|
-
|
|
Mar 22
2024
|
Klara Dickinson Chief Regulatory Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,000
-100.0%
|
-
|
|
Mar 22
2024
|
Harish Shantharam Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,125
-100.0%
|
-
|
|
Mar 22
2024
|
Sujal Shah Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
406,670
-100.0%
|
-
|
|
Mar 22
2024
|
Robert James Wills |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,000
-100.0%
|
-
|
|
Mar 22
2024
|
Paul T Quinlan General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
70,262
-100.0%
|
-
|
|
Mar 22
2024
|
Kurt Von Emster |
SELL
Sale (or disposition) back to the issuer
|
Direct |
90,000
-100.0%
|
-
|
|
Mar 13
2024
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
41,824
+37.31%
|
$292,768
$7.89 P/Share
|
|
Mar 13
2024
|
Sujal Shah Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
139,119
+4.11%
|
$834,714
$6.1 P/Share
|
|
Feb 12
2024
|
Janet Dorling |
SELL
Open market or private sale
|
Direct |
6,000
-100.0%
|
$186,000
$31.97 P/Share
|
|
Feb 12
2024
|
Janet Dorling |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$24,000
$4.63 P/Share
|
|
Jan 24
2024
|
Charles Mc Wherter President of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
31,938
+40.49%
|
-
|
|
Jan 24
2024
|
Klara Dickinson Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+50.0%
|
-
|
|
Jan 24
2024
|
Harish Shantharam Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,125
+50.0%
|
-
|
|
Jan 24
2024
|
Sujal Shah Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,250
+26.46%
|
-
|
|
Jan 24
2024
|
Paul T Quinlan General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
28,438
+50.0%
|
-
|
|
Jan 19
2024
|
Charles Mc Wherter President of R&D |
SELL
Open market or private sale
|
Direct |
18,403
-18.59%
|
$423,269
$23.67 P/Share
|
|
Jan 19
2024
|
Charles Mc Wherter President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
18,403
+15.25%
|
$92,015
$5.26 P/Share
|
|
Jan 16
2024
|
Paul T Quinlan General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$115,000
$23.58 P/Share
|
|
Jan 16
2024
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.94 P/Share
|
|
Jan 16
2024
|
Daniel Menold Vice President, Finance |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$230,000
$23.58 P/Share
|
|
Jan 16
2024
|
Daniel Menold Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$40,000
$4.05 P/Share
|
|
Jan 10
2024
|
Janet Dorling |
SELL
Open market or private sale
|
Direct |
6,000
-100.0%
|
$138,000
$23.86 P/Share
|
|
Jan 10
2024
|
Janet Dorling |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$24,000
$4.63 P/Share
|